Background. Concurrent use of sedatives, especially anxiolytics, and opioids is associated with
Objectives. Describe the proportion of new opioid recipients with concurrent sedative medications at opioid initiation and determine whether these medications were prescribed by the same prescriber.
Methods. We used national Department of Veterans Affairs (VA) outpatient pharmacy administration data to identify veterans who received a new opioid prescription between October 20, 2010, and September 1, 2011 (FY 2011) , preceded by a 365-day opioid-free period. Concurrent sedative use was defined as a skeletal muscle relaxant, benzodiazepine, atypical antipsychotic, or hypnotic filled on the opioid start date or before and after the opioid start date with a gap of less than twice the day supply of the prior fill.
Results. Concurrent sedative use at opioid initiation was 21.4% (112,408/526,499) in FY 2011. The proportion of concurrent recipients who received at least one concurrent sedative prescribed by a provider other than the opioid prescriber was 61.4% (69,002/112,408). The proportion of recipients who received a sedative concurrent with opioid initiation from the same prescriber varied across sedative class. Benzodiazepines and opioids were prescribed by the same provider in 41.1% (15,520/ 37,750) of concurrent users. Conclusion. One in five patients newly prescribed opioids also had a sedative prescription. Less than half of patients with concurrent opioid and benzodiazepine prescriptions received these from the same provider. Efforts to reduce concurrent opioid and sedative prescribing will require addressing care coordination.
Key Words. Opioids; Sedatives; Benzodiazepines; Coprescribing; Veterans Background Concurrent use of sedatives, especially anxiolytics, and opioids is associated with greater risk of medication-related harms [1] [2] [3] [4] . While recent work indicates that the use and abuse of opioid analgesics may be plateauing or decreasing in the United States since around 2011 [5, 6] , coprescription of sedatives and opioids remains an important public health concern [4, 7, 8] .
Efforts to reduce high-dose opioid prescribing by primary care providers within the Veterans Administration (VA) have demonstrated early success [9] . The Veterans Health Administration's (VHA's) Opioid Safety Initiative also monitors the coprescription of benzodiazepines and opioids to ensure safe and effective use of opioid analgesics. However, implementing change to coprescribing pattern presents added challenges compared with changing prescribing patterns within a single drug class. Coprescription may arise from a single provider or from multiple providers; it may reflect attempts to use multiple drug classes to treat a single condition or to treat multiple comorbid conditions. Same provider coprescription and different provider coprescription are likely sensitive to distinct interventions.
While prior studies have reported rates, trends, and patient-level correlates of opioid and sedative coprescription in patients with pain or receiving long-term opioids [6, 10, 11] , none have examined coprescription at opioid initiation or distinguished coprescription by the same vs a different provider. Understanding the relative contributions of single and multiple providers to coprescribing remains a key question [7] . Therefore, to better inform interventions to support safe and cautious prescribing, we describe the proportion of new opioid users who were receiving concurrent sedative medications at the time of opioid initiation. Additionally, we determined whether these medications were prescribed by the same provider.
Methods

Data Source
National administrative VHA data were obtained through the Austin Information Technology Center for fiscal years (FY) 2010 through 2012 (Austin, TX, USA). Decision Support System National Data Extracts for inpatient and outpatient care were used to identify opioid medication dispensing events, diagnostic codes, and outpatient encounters. This study was approved by the University of Iowa Institutional Review Board and the Iowa City VA Healthcare System Research and Development Committee.
Target Population
New opioid recipients (i.e., incident recipients) were identified by an opioid dispensed in the outpatient setting during FY2011 (October 1, 2010, to September 30, 2011) with no opioids dispensed during the prior 365 days. Selection criteria based on demonstrated history of VHA service were not applied; these criteria may be overly restrictive and did not substantially affect results in prior work [12, 13] . Patients were excluded if they had metastatic cancer (ICD-9 codes 196.x-199.x) or hospice or palliative care services at any point in the year prior to or following the opioid initiation date; the intent of prescribing in these patient populations may be distinct from those in noncancer or nonpalliative practice, and coprescription may be consistent with these goals. Hospice and palliative care services were identified by VHA clinic stop codes 351 or 353 in outpatient encounter data and by ICD-9 code V667 or bedsection code 96 in the inpatient hospitalization data. Patients were also excluded if they had an outpatient visit to an opioid substitution clinic (stop code 523) at any point during the year prior to or within the first 30 days following opioid initiation because it was assumed that these patients were unlikely to be opioid naïve, although an opioid identified in the administrative data may be newly prescribed.
Concurrent Medications
Coprescribed medications of interest included skeletal muscle relaxants, benzodiazepines, atypical antipsychotics, and hypnotics (zolpidem, eszopiclone, zaleplon, and ramelteon), heretofore referred to generally as sedatives. Sedative use at the time of opioid initiation was divided into two mutually exclusive categories, concurrent initiation and continued use. Concurrent initiation was defined as a sedative filled on the same day as the opioid start date, with no fills in the prior year. Continued use was defined as a sedative filled both before and after the opioid start date where the time between these fills was less than or equal to twice the day supply of the pre-opioid fill [11] .
Analysis
The proportion of concurrent and continued opioidsedative use was analyzed using population data; therefore, no sample inference statistics were calculated. All analyses were conducted using SAS version 9.3 (Cary, NC, USA).
Results
Continued Use and Same-Day Starts
Of the 526,499 veterans who initiated opioid therapy in FY 2011, 112,408 (21.4%) had coprescription of at least one sedative (Table 1 ). The most common medication class used at opioid initiation was skeletal muscle Sedative and Opioid Coprescribing Trends relaxants (10.8%), followed by benzodiazepines (7.2%), atypical antipsychotics (3.7%), and hypnotics (2.9%).
The proportion of veterans for whom opioids and sedatives were initiated on the same day varied by medication class (Table 1) . Among veterans prescribed skeletal muscle relaxants 45,050 of 56,735 (79.4%) received opioids on the same day. In contrast, 13,229 of 37,750 (35.0%) concurrently initiated benzodiazepines, as did a similar proportion who received hypnotics (5,283/ 15,241, 34.7%).
Coprescription by Same Provider (Concordant Prescription)
The proportion who were coprescribed a sedative and had an opioid initiated by the same provider (concordant prescription) varied across medication class. Skeletal muscle relaxants were prescribed concordantly with opioids in 85.1% of cases, followed by benzodiazepines (Table 2) . Atypical antipsychotics were prescribed by the same prescriber in 13.1% of cases. When only coprescriptions resulting from same-day starts were considered, sedatives and opioids were prescribed by the same provider in the majority of cases for skeletal muscle relaxants, hypnotics, and benzodiazepines, and in just under half of cases where atypical antipsychotics were prescribed. In comparison, concordant prescription occurred less often when sedative prescription preceded opioid initiation ( Table 2) .
Frequency of Prescribed Sedatives
Cyclobenzaprine accounted for 61.3% (34,769/56,735) of the muscle relaxants prescribed. Zolpidem accounted for 98.7% (15,037/15,241) of coprescribed hypnotics. Long-acting benzodiazepines (clonazepam and diazepam) accounted for 41.6% (16,465/37,750) of prescribed benzodiazepines (Table 3) .
Discussion
Reported prevalence of sedative use in patients prescribed opioids varies based on population studied, cohort selection, and exposure definitions. One-third of patients with chronic noncancer pain and long-term opioid use reported benzodiazepine use in one national sample study [14] . An estimated one in four veterans who received opioid analgesics between 2004 and 2009 received benzodiazepines as well [3] . Among patients receiving opioids in North Carolina in 2010, eight in 10 were prescribed benzodiazepines in the previous year [4] . Our study is the first, to our knowledge, to report concurrent prescribing at initial opioid prescription and to detail if both sedative and opioid prescriptions originated from the same or different providers.
That approximately two in 10 patients with a new opioid prescription were receiving a concurrent sedative adds to our understanding of the scope of polysedative use. More importantly, our work demonstrates that while Table 2 Proportion of sedative recipients with the same prescriber as the index opioid by timing of sedative receipt
Sedative recipients with the same prescriber as the index opioid
Sedative class
Overall n/N (%) Same-day starts n/N (%) Pre-existing sedative n/N (%) opioids are often initiated by the same prescriber in cases of skeletal muscle relaxants, coprescribing of benzodiazepines, atypical antipsychotics, or hypnotics and opioids commonly results from prescriptions originating from different providers and at different times. Interestingly, even in cases in which patients received opioid and sedative prescriptions on the same day, approximately one in five of coprescribed benzodiazepines and hypnotics originated from different providers. One scenario in which this might occur is a patient who has a primary care and specialty visit scheduled on the same day.
Our findings that, with the exception of skeletal muscle relaxants, sedative and opioid coprescribing commonly arose from different providers have implications to efforts to reduce prescribing of potentially dangerous drug combinations. In a large cohort, rates of overdose death in patients coprescribed benzodiazepines and opioids were 10 times higher than those on opioid analgesics alone [4] . The coprescribing patterns we identified occurred in the VHA, an integrated health system in which prescribers can readily view all medications being prescribed and dispensed through the VA pharmacy. The relatively high rate of concurrent prescription from different providers suggests that even where barriers to reviewing existing prescriptions are relatively low (i.e., do not require accessing out-of-system medical or pharmacy records, or state Prescription Drug Monitoring Databases), patients are receiving concurrent sedatives and opioids.
Future research may better characterize prescriber type (specialty) and conditions associated with sedative and opioid combinations; continued exploration of safe and effective alternate modalities to address conditions currently treated with risky medication combinations is needed. Strategies such as provider education or academic detailing may be less effective when coprescribing originates from multiple prescribers. Mechanisms to facilitate care coordination, including forcing functions to hold prescriptions until care coordination is documented, might be considered. As opioid initiation appears to be an important decision point in reducing prescribing of potentially harmful drug combinations, increased scrutiny of new prescriptions may be effective.
This brief report has a number of limitations: We were not able to determine provider type (e.g., primary, specialty, psychiatric), nor did we examine patient characteristics or describe opioid course or patient-level outcomes following initial opioid prescription. Our study was limited to a veteran population that utilized VA care between FY2010 and FY2011 and included only VAprescribed medications.
Conclusions
Coprescription of sedatives and opioid analgesics is common. Benzodiazepines and opioids, the most concerning combination, are prescribed by different providers at the time of opioid initiation in the majority of cases. Based on the observed patterns, efforts to reduce coprescription will require systems approaches to facilitate care coordination where different providers are contributing to concurrent sedative and opioid prescribing.
